Table 2 Clinical characteristics of patients with myelodysplastic neoplasms, categorized by the 2022 World Health Organization classification.

From: Comparison of the 2022 world health organization classification and international consensus classification in myelodysplastic syndromes/neoplasms

View full size image

  1. Data are presented as n (%). P values of <0.05 are statistically significant.
  2. AML acute myeloid leukemia, ANC absolute neutrophil count, MDS myelodysplastic neoplasms, 5q MDS with low blasts and isolated 5q deletion, biTP53 MDS with biallelic TP53 inactivation, f MDS with fibrosis, h MDS hypoplastic, Hb hemoglobin, HMA hypomethylating agent, HSCT hematopoietic stem cell transplantation, IB1 MDS with increased blasts-1, IB2 MDS with increased blasts-2, IPSS-R revised international prognosis scoring system, IPSS-M molecular international prognosis scoring system, LB MDS with low blasts, RS ring sideroblasts, SF3B1 MDS with low blasts and SF3B1 mutation.
  3. *Median.
  4. †Other treatment: include low-dose cytarabine, rabbit-derived anti-thymocyte globulin (rATG), cyclosporine, danazol, eltrombopag, erythropoietin-stimulating agents (ESA), thalidomide, steroid, venetoclax-based therapy and oral chemotherapy.
  5. §Death within 3 months of diagnosis.
Back to article page